QUOTE AND NEWS
FiercePharma  Sep 11  Comment 
Yesterday, Orexigen won FDA approval for its obesity drug Contrave, but with a "black box" warning on side effects. And patients could have yet another weight-loss choice, as a panel of FDA advisers meet today to weigh Novo Nordisk's rival drug,...
Benzinga  Sep 11  Comment 
Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. (Nasdaq: OREX) jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Contrave® (naltrexone HCI and bupropion HCI) extended-release tablets as an...
Forbes  Sep 10  Comment 
The FDA announced today that it had approved Contrave, the long-awaited and much-disputed weight loss drug.  The drug is a combination of two drugs already approved for other indications: naltrexone hydrochloride, which is used to combat alcohol...
StreetInsider.com  Sep 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Orexigen+Therapeutics+%28OREX%29%2C+Takeda+Enter+Manufacturing+Services+Agreement+Covering+NB32/9814894.html for the full story.
GenEng News  Sep 3  Comment 
AbbVie will join Infinity Pharmaceuticals to develop and commercialize the latter’s lead R&D program, focused on the cancer compound duvelisib (IPI-145), the companies said today. The deal could generate up to $805 million for Infinity, which...
MedPage Today  Aug 29  Comment 
(MedPage Today) -- Topline results from a 10-year analysis of diabetic patients treated with pioglitazone (Actos) indicated no increased risk of bladder cancer, even with long-term use, the drug's manufacturer said.
FiercePharma  Aug 29  Comment 
Legal experts have insisted there is no way that a $9 billion punitive damage award against Takeda Pharmaceutical and Eli Lilly for hiding Actos risks can stand. But the two companies are still sweating that one out after a federal judge refused...
FiercePharma  Aug 11  Comment 
Takeda Pharmaceuticals' new French-born CEO knows he is seen as an outsider by many Japanese, including some of Takeda's alumni. He appreciates their concerns and says Takeda will remain a Japanese-based company, true to its heritage. But he also...
Japan Today  Aug 6  Comment 
Japan's biggest drugmaker Takeda Pharmaceutical Co will become more selective in its choice of research and development projects, its newly appointed president said, as the company struggles with shrinking margins due to a dearth of new...




 
TOP CONTRIBUTORS

No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki